title: Regional brain metabolic response to lorazepam in alcoholics during early and late alcohol detoxification.
abstract: Changes in GABA function have been postulated to be involved in alcohol tolerance, withdrawal and addiction. In this study we measured regional brain metabolic responses to lorazepam, to indirectly assess GABA function (benzodiazepines facilitate GABAergic neurotransmission), in alcoholics during early and late withdrawal. Brain metabolism was measured using PET and 2-deoxy-2[18F]fluoro-D-glucose after placebo (baseline) and after lorazepam (30 micrograms/kg intravenously) in 10 alcoholics and 16 controls. In the alcoholics evaluations were performed 2 to 3 weeks after detoxification and were repeated 6 to 8 weeks later. Controls were also evaluated twice at a 6 to 8 weeks interval. While during the initial evaluation metabolism was significantly lower for most brain regions in the alcoholics than in controls in the repeated evaluation the only significant differences were in cingulate and orbitofrontal cortex. Lorazepam-induced decrements in metabolism did not change with protracted alcohol withdrawal and the magnitude of these changes were similar in controls and alcoholics except for a trend towards a blunted response to lorazepam in orbitofrontal cortex in alcoholics during the second evaluation. Abnormalities in orbitofrontal cortex and cingulate gyrus in alcoholics are unlikely to be due to withdrawal since they persist 8 to 11 weeks after detoxification. The fact that there was only a trend of significance for an abnormal response to lorazepam in orbitofrontal cortex indicates that mechanisms other than GABA are involved in the brain metabolic abnormalities observed in alcoholic subjects.
authors.affiliation: Medical Department, Brookhaven National Laboratory, Upton, New York 11973, USA.
authors.forename: N D
authors.initials: ND
authors.lastname: Volkow
authors.forename: G J
authors.initials: GJ
authors.lastname: Wang
authors.forename: J E
authors.initials: JE
authors.lastname: Overall
authors.forename: R
authors.initials: R
authors.lastname: Hitzemann
authors.forename: J S
authors.initials: JS
authors.lastname: Fowler
authors.forename: N
authors.initials: N
authors.lastname: Pappas
authors.forename: E
authors.initials: E
authors.lastname: Frecska
authors.forename: K
authors.initials: K
authors.lastname: Piscani
mesh_terms: D000328:Adult; D000430:Alcohol Withdrawal Delirium / Q000503:physiopathology / Q000534:rehabilitation*; D000437:Alcoholism / Q000503:physiopathology / Q000534:rehabilitation*; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D001931:Brain Mapping; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D005625:Frontal Lobe / Q000187:drug effects / Q000503:physiopathology; D018757:GABA Modulators / Q000494:pharmacology*; D006179:Gyrus Cinguli / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008140:Lorazepam / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D017397:Prefrontal Cortex / Q000187:drug effects / Q000503:physiopathology; D012016:Reference Values; D014055:Tomography, Emission-Computed
chemical_list: D001786:Blood Glucose; D018757:GABA Modulators; D019788:Fluorodeoxyglucose F18; D008140:Lorazepam